



# Biomap

Biomarkers in Atopic Dermatitis and Psoriasis

## Why do some people get more severe disease?

**Virtual webinar:**

Developing better treatments for eczema and psoriasis:  
what we've learned from the BIOMAP research

25<sup>th</sup> March 2025

Lavinia Paternoster

University of Bristol



MRC Integrative  
Epidemiology  
Unit



University of  
BRISTOL



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821511. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

## Why study disease severity?



**Psoriasis and eczema vary in how severe the condition is between people**

If we can find the biological reasons for these differences, this can provide useful information about how best to intervene to improve the condition

## Overview


- How we have approached studying disease severity in BIOMAP
- Eczema severity study
- Psoriasis severity study
- Future patient impact

## Severity - The BIOMAP approach



**Extensive clinical/trial datasets  
with validated scores:**


eczema: EASI/SCORAD  
Psoriasis: PASI



**Large-scale genetic biobanks with  
data from electronic health records:**

- Hospitalisation
- Use of certain medication


# Eczema Severity Study



## Psoriasis Severity Study

Genetic variants associated with psoriasis onset also impact disease severity:

- Genetic risk may be as important as lifestyle factors for disease severity
- **Future potential:** predict how severe someone's disease might become



## Future impact for patients



### Scientific success:



Improved understanding  
of the mechanisms  
(e.g. genes)  
that influence severe  
eczema and psoriasis



### Future impact:



Lead to new treatments – that may  
work for the most severe disease



Potential ability to predict who will  
suffer the most severe disease – and  
treat to prevent this